[6-K] GSK plc American Current Report (Foreign Issuer)
GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 录 pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.
GSK plc ha presentato un Modulo 6-K per conformarsi alla Regola 5.6.1R della Financial Conduct Authority (FCA) relativa alla Guida alla Trasparenza e alla Comunicazione. Al 31 luglio 2025, la societ脿 aveva 4.315.385.410 azioni ordinarie emesse del valore nominale di 31 录 pence ciascuna. Di queste, 237.044.421 azioni erano detenute in tesoreria, lasciando 4.078.340.989 diritti di voto in circolazione. Gli azionisti devono utilizzare questo denominatore per calcolare le notifiche di soglia delle partecipazioni secondo le regole FCA. L鈥檃vviso 猫 stato autorizzato dal Segretario della Societ脿 V. A. Whyte e depositato il 1掳 agosto 2025.
GSK plc ha presentado un Formulario 6-K para cumplir con la Regla 5.6.1R de la Autoridad de Conducta Financiera (FCA) sobre Orientaci贸n de Divulgaci贸n y Transparencia. Al 31 de julio de 2025, la compa帽铆a ten铆a 4.315.385.410 acciones ordinarias emitidas de 31 录 peniques cada una. De estas, 237.044.421 acciones se manten铆an en tesorer铆a, quedando 4.078.340.989 derechos de voto en circulaci贸n. Los accionistas deben usar este denominador al calcular las notificaciones de umbral de participaciones seg煤n las reglas de la FCA. El aviso fue autorizado por el Secretario de la Compa帽铆a V. A. Whyte y presentado el 1 de agosto de 2025.
GSK plc電� 旮堨湹頄夒彊臧愲弲觳�(FCA)鞚� 瓿奠嫓 歆�旃� 氚� 韴獏靹� 攴滌箼 5.6.1R鞚� 欷�靾橅晿旮� 鞙勴暣 Form 6-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 31鞚� 旮办鞙茧 須岇偓電� 臧侁皝 31 录 韼滌姢鞚� 鞎‰┐臧�毳� 臧�歆� 4,315,385,410欤检潣 氤错喌欤茧ゼ 氚滍枆頄堨姷雼堧嫟. 鞚� 欷� 237,044,421欤茧姅 鞛愳偓欤茧 氤挫湢霅橃柎 鞛堨柎, 鞙犿喌 欷戩澑 4,078,340,989臧滌潣 鞚橁舶甓岇澊 雮晞 鞛堨姷雼堧嫟. 欤检＜霌れ潃 FCA 攴滌爼鞐� 霐半ジ 氤挫湢 歆�攵� 鞛勱硠旃� 鞁犼碃 鞁� 鞚� 攵勲毳� 靷毄頃挫暭 頃╇媹雼�. 鞚� 瓿奠電� 須岇偓 牍勳劀 V. A. Whyte鞐� 鞚橅暣 鞀轨澑霅橃棃鞙茧┌ 2025雲� 8鞗� 1鞚检棎 鞝滌稖霅橃棃鞀惦媹雼�.
GSK plc a d茅pos茅 un formulaire 6-K afin de se conformer 脿 la r猫gle 5.6.1R de la Financial Conduct Authority (FCA) relative aux directives de divulgation et de transparence. Au 31 juillet 2025, la soci茅t茅 d茅tenait 4 315 385 410 actions ordinaires 茅mises d鈥檜ne valeur nominale de 31 录 pence chacune. Parmi celles-ci, 237 044 421 actions 茅taient d茅tenues en tr茅sorerie, laissant 4 078 340 989 droits de vote en circulation. Les actionnaires doivent utiliser ce d茅nominateur pour calculer les notifications de seuil conform茅ment aux r猫gles de la FCA. L鈥檃vis a 茅t茅 autoris茅 par le secr茅taire de la soci茅t茅 V. A. Whyte et d茅pos茅 le 1er ao没t 2025.
GSK plc hat ein Formular 6-K eingereicht, um die Offenlegungsleitlinie und Transparenzregel 5.6.1R der Financial Conduct Authority (FCA) zu erf眉llen. Zum 31. Juli 2025 hatte das Unternehmen 4.315.385.410 ausgegebene Stammaktien mit einem Nennwert von jeweils 31 录 Pence. Davon befanden sich 237.044.421 Aktien im eigenen Bestand, sodass 4.078.340.989 Stimmrechte im Umlauf sind. Aktion盲re sollten diesen Nenner bei der Berechnung von Schwellenwertmeldungen gem盲脽 den FCA-Vorschriften verwenden. Die Mitteilung wurde vom Company Secretary V. A. Whyte genehmigt und am 1. August 2025 eingereicht.
- None.
- None.
Insights
TL;DR: Routine share-count update; 4.08 bn voting rights outstanding, no dilution or buyback signalled鈥攙aluation impact neutral.
The filing simply refreshes the market on GSK鈥檚 share count and treasury position in line with FCA Rule 5.6.1R. No share issuances, cancellations or buy-back activity are disclosed, so equity value per share and EPS math remain unchanged. Investors may update their models to reflect 4.078 bn voting rights but should not expect financial or strategic implications from this administrative notice.
TL;DR: Governance-driven disclosure; ensures transparency for substantial holding notifications, otherwise immaterial.
Filing maintains compliance with UK transparency rules by publicly stating the precise denominator for ownership threshold calculations. The presence of 237 m treasury shares equates to c.5.5% of issued capital, giving the board flexibility for incentive plans or future buy-backs, yet today鈥檚 notice does not commit to any action. Impact on governance assessments is neutral.
GSK plc ha presentato un Modulo 6-K per conformarsi alla Regola 5.6.1R della Financial Conduct Authority (FCA) relativa alla Guida alla Trasparenza e alla Comunicazione. Al 31 luglio 2025, la societ脿 aveva 4.315.385.410 azioni ordinarie emesse del valore nominale di 31 录 pence ciascuna. Di queste, 237.044.421 azioni erano detenute in tesoreria, lasciando 4.078.340.989 diritti di voto in circolazione. Gli azionisti devono utilizzare questo denominatore per calcolare le notifiche di soglia delle partecipazioni secondo le regole FCA. L鈥檃vviso 猫 stato autorizzato dal Segretario della Societ脿 V. A. Whyte e depositato il 1掳 agosto 2025.
GSK plc ha presentado un Formulario 6-K para cumplir con la Regla 5.6.1R de la Autoridad de Conducta Financiera (FCA) sobre Orientaci贸n de Divulgaci贸n y Transparencia. Al 31 de julio de 2025, la compa帽铆a ten铆a 4.315.385.410 acciones ordinarias emitidas de 31 录 peniques cada una. De estas, 237.044.421 acciones se manten铆an en tesorer铆a, quedando 4.078.340.989 derechos de voto en circulaci贸n. Los accionistas deben usar este denominador al calcular las notificaciones de umbral de participaciones seg煤n las reglas de la FCA. El aviso fue autorizado por el Secretario de la Compa帽铆a V. A. Whyte y presentado el 1 de agosto de 2025.
GSK plc電� 旮堨湹頄夒彊臧愲弲觳�(FCA)鞚� 瓿奠嫓 歆�旃� 氚� 韴獏靹� 攴滌箼 5.6.1R鞚� 欷�靾橅晿旮� 鞙勴暣 Form 6-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 31鞚� 旮办鞙茧 須岇偓電� 臧侁皝 31 录 韼滌姢鞚� 鞎‰┐臧�毳� 臧�歆� 4,315,385,410欤检潣 氤错喌欤茧ゼ 氚滍枆頄堨姷雼堧嫟. 鞚� 欷� 237,044,421欤茧姅 鞛愳偓欤茧 氤挫湢霅橃柎 鞛堨柎, 鞙犿喌 欷戩澑 4,078,340,989臧滌潣 鞚橁舶甓岇澊 雮晞 鞛堨姷雼堧嫟. 欤检＜霌れ潃 FCA 攴滌爼鞐� 霐半ジ 氤挫湢 歆�攵� 鞛勱硠旃� 鞁犼碃 鞁� 鞚� 攵勲毳� 靷毄頃挫暭 頃╇媹雼�. 鞚� 瓿奠電� 須岇偓 牍勳劀 V. A. Whyte鞐� 鞚橅暣 鞀轨澑霅橃棃鞙茧┌ 2025雲� 8鞗� 1鞚检棎 鞝滌稖霅橃棃鞀惦媹雼�.
GSK plc a d茅pos茅 un formulaire 6-K afin de se conformer 脿 la r猫gle 5.6.1R de la Financial Conduct Authority (FCA) relative aux directives de divulgation et de transparence. Au 31 juillet 2025, la soci茅t茅 d茅tenait 4 315 385 410 actions ordinaires 茅mises d鈥檜ne valeur nominale de 31 录 pence chacune. Parmi celles-ci, 237 044 421 actions 茅taient d茅tenues en tr茅sorerie, laissant 4 078 340 989 droits de vote en circulation. Les actionnaires doivent utiliser ce d茅nominateur pour calculer les notifications de seuil conform茅ment aux r猫gles de la FCA. L鈥檃vis a 茅t茅 autoris茅 par le secr茅taire de la soci茅t茅 V. A. Whyte et d茅pos茅 le 1er ao没t 2025.
GSK plc hat ein Formular 6-K eingereicht, um die Offenlegungsleitlinie und Transparenzregel 5.6.1R der Financial Conduct Authority (FCA) zu erf眉llen. Zum 31. Juli 2025 hatte das Unternehmen 4.315.385.410 ausgegebene Stammaktien mit einem Nennwert von jeweils 31 录 Pence. Davon befanden sich 237.044.421 Aktien im eigenen Bestand, sodass 4.078.340.989 Stimmrechte im Umlauf sind. Aktion盲re sollten diesen Nenner bei der Berechnung von Schwellenwertmeldungen gem盲脽 den FCA-Vorschriften verwenden. Die Mitteilung wurde vom Company Secretary V. A. Whyte genehmigt und am 1. August 2025 eingereicht.
FAQ
How many voting rights does GSK (GSK) report as of 31 July 2025?
What is GSK plc鈥檚 total issued share capital on 31 July 2025?
How many GSK shares are held in treasury?
Why is the voting rights figure important for shareholders?
When was this information filed and in what form?
